相关实验视频
Updated: Jun 8, 2025

03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
5.2K
糖尿病管理中的持续葡萄糖监测器 (CGM) 的比较:系统性文献综述
Rosilla Edward1, Ronny Priefer1
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA.
Primary care diabetes
|November 4, 2024
概括
连续血糖监测器 (CGM) 改善了1型和2型糖尿病的糖尿病管理. 虽然所有主要的CGM都显示出类似的益处,但最佳选择取决于个人的血糖控制目标.
科学领域:
- 内分泌学 在内分泌学.
- 医疗器械 医疗器械
- 糖尿病管理 糖尿病管理
背景情况:
- 全球糖尿病患病率不断上升,需要先进的疾病管理.
- 连续葡萄糖监测器 (CGM) 从传统方法有了显著的进化.
- 主要的CGM竞争对手包括Medtronic,Dexcom,Freestyle和Eversense. 这些公司是CGM的主要竞争对手.
研究的目的:
- 评估流行的连续葡萄糖监测器 (CGM) 在糖尿病管理中的有效性.
- 为了比较美国市场领先的CGM设备的性能.
主要方法:
- 系统审查PubMed学术文章和补充手稿.
- 在过去的20年里,对现实世界的数据和设备性能指标的分析.
主要成果:
- CGMs在血糖水平管理方面显示出临床改善.
- 平均绝对相对差异 (MARD) 是评估CGM有效性的关键指标.
- 所有领先的CGM设备对T1DM和T2DM患者显示了可比的益处.
结论:
- 领先的CGM为糖尿病管理提供了类似的优势.
- 个人CGM选择应与特定的患者目标保持一致,例如范围内的时间 (TIR) 或A1c减少.
- 在不同患者群体中,CGM是实现血糖控制的宝贵工具.
相关概念视频
Diabetes: Management and Pharmacotherapy
236
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes: Symptoms, Diagnosis, and Complications
508
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
508
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
Oral Hypoglycemic Agents: Glinides
141
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
141

